全球网站 |
Media Report 99
he China Red Ribbon Foundation has launched an annual program to advocate knowledge about HIV and AIDS prevention among migrant workers.
HIV-prevention program targets migrant workers
Source: Ecns.cn
The China Red Ribbon Foundation has launched an annual program to advocate knowledge about HIV and AIDS prevention among migrant workers.
The program, which began on Wednesday and will be an annual event, recruits university students as volunteers to give "health bags" to migrant workers. Each bag includes such items as a pamphlet and a deck of cards printed with facts about HIV prevention, a cup, a mask, a nail cutter, a handkerchief and a pair of gloves.
The volunteers will also share knowledge about HIV prevention with the migrant workers through such means as lectures and games. More…
02/07/2014
HIV-Positive Students Sit Senior High School Entrance Exams
Source: Womenofchina.cn
Sixteen children affected by HIV in the Linfen Red Ribbon School in north China's Shanxi Province, sat their senior high school entrance exams on June 20, meaning that the school will have senior high school students in the new semester for the first time.
New teachers from a local leading senior high school will join the school and teach them in the next three years, despite the fact that the school's name won't appear on the children's graduation certificates.
Established in 2006 by President of the Linfen Hospital for Infectious Diseases Guo Xiaoping, the Linfen Red Ribbon School is China's first and only school for children affected by HIV/AIDS.
The school, which offers primary and junior middle school education, now has a total of 25 students, 16 of whom are in the third year of junior middle school.
During the first six years, the school ran without certification, so students could not register in the local education system, had no graduation certificate, and were not allowed to attend the high school entrance exam. In October 2011, the local government approved the school's certification and granted subsidies. More…
03/07/2014
Clinical, immunological, and virological outcomes of pediatric antiretroviral therapy in central China
Source: 7thspace.com/
Antiretroviral therapy (ART) reduces HIV-related mortality and morbidity substantially in children. The clinical characteristics, immunological and virological outcomes were evaluated in HIV-infected children receiving ART.
Methods: Twenty-six HIV-1-infected children receiving ART in Hubei province, China, were enrolled retrospectively in this study.
During the period of ART, plasma viral load, lymphocyte phenotype of CD4 and CD8 cells and clinical events were assessed.
Results: The median duration of ART was 41 months (18-72.3 months). In children showing clinical improvement, high viral suppression rate below log10 (2.7) copies/ml by the third months of ART was observed.
The median CD4 cell counts reached to 820.5/mul by 12 months and the median ratio of CD4/CD8 increased to 0.6 by 21 months. The counts of peripheral white blood cells and red blood cells decreased in the first 12 months, while Hb concentration, MCV and MCH increased (P <0.001).More…
06/07/2014
Should You Take a Chance With GlaxoSmithKline?
Source: wallstcheatsheet.com/
With shares of GlaxoSmithKline (NYSE:GSK) trading around $54, is GSK an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let’s analyze the stock with the relevant sections of our CHEAT SHEET investing framework:
T = Trends for a Stock’s Movement
GlaxoSmithKline is global healthcare group engaged in the discovery, development, manufacturing, and marketing of pharmaceutical products. These products are vaccines, over-the-counter medicines, and health-related consumer products. GlaxoSmithKline’s principal pharmaceutical products are medicines in these areas: respiratory, antivirals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV.
Peter Humphrey had not expected to be caught in the glare of a television camera from China Central Television, the state broadcaster, when he was escorted last August into a small room in a Shanghai detention centre. Humphrey, a British private investigator hired by GlaxoSmithKline to investigate whether a former Chinese employee was waging a smear campaign against the company, was asked to read a confession into what he was told would be a small police interrogation camera, according to people familiar with his case. Police informed him that it would help his situation. A month earlier Humphrey and Yu Yingzeng, his American wife and business partner, had been arrested on charges of illegally purchasing private information and operating an illegal business. Handcuffed and wearing an orange prison vest, Humphrey instead found himself recording a confession that would later be broadcast across the country. “He had no choice but to say what he had been told to say in front of a big camera instead of a small one,” said one person familiar with the trap. “He was extremely upset about it afterwards and the British government complained.” Shanghai police declined to comment. More…
08/07/2014
Research and Markets: Global Flow Cytometry Market Forecasts and Opportunities, 2018: Technology, Products & Services, Application & End User Analysis
Source:heraldonline.com
In this report, the global flow cytometry market has been segmented on the basis of products (instruments, reagents and consumables, software, services, and accessories) and applications (research, clinical, and industrial applications). The Research field commands a major chunk of the global flow cytometry market in 2013. This is attributed to the increasing applications of flow cytometry in drug discovery and development process, right from pre-clinical trials to target identification and throughput screening. However, the clinical applications segment is the fastest growing segment in this market, owing to the increasing prevalence coupled with intensifying adoption of flow cytometry techniques for the diagnosis and treatment of a number of diseases such as cancer, HIV/AIDS, and others.
The global flow cytometry market is dominated by North America, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). North America will continue to dominate the market in the forecast period (2013-2018). However, the Asia-Pacific region is expected to grow at the highest CAGR of 16% from 2013 to 2018.
Over the next five years, the growth of the market in the Asia-Pacific region is likely to be centered at Japan, China, and India. A number of factors such as various economic developments and growing prevalence to HIV/AIDS, growing number of research initiatives, increasing government support, growing awareness, and growing focus of both international and domestic players are driving the growth of the market in the Asia-Pacific region.
New product launches is the key strategy followed by the leading market players to ensure their growth in the market. Moreover, partnerships, agreements, collaborations and joint ventures, mergers and acquisitions, and expansions are some other growth strategies adopted by the industry players in the global market. More…
08/07/2014
The Dangerous Resurgence of Tuberculosis in China
Source: counterpunch.org
China now has the second largest tuberculosis epidemic -second only to India- with more than 1.3 million new cases of tuberculosis every year. What makes the situation particularly serious, however, is that, according to the Chinese Center for Disease Control, China has the largest number of patients with Multiple Drug Resistant Tuberculosis (MDR-TB), and that Extremely Resistant Drug Tuberculosis (XDR-TB) is also widespread. These facts show the need to step up efforts to combat the disease.
In 1993, the World Health Organization (WHO) instituted a cost-effective treatment of tuberculosis called DOTS (a directly observed treatment of a short course of drugs) that was very effective in combating TB in low-income countries. However, over time, patients began developing resistance to the drugs used for treatment, causing MDR-TB to spread.
Less than one-quarter of those believed to have MDR-TB have been diagnosed, according to the WHO, which facilitates the spreading of this serious form of the disease. “We have managed by a combination of complacency and incompetence to allow this bacillus to mutate to a virtually untreatable form,” wrote Dr. Zarir Udwadia, an Indian world expert on tuberculosis and author of the book Principles of Respiratory Medicine.
Tuberculosis becomes resistant to drugs in patients who don’t complete the treatment. The current treatment for non-resistant tuberculosis is relatively cheap and consists of drugs called first-line drugs for TB. In MDR-TB the patient is resistant to at least the two most powerful anti-TB drugs. This form of the disease is much more costly to treat, and it is also much more toxic (it has more serious side effects), which explains patients’ reluctance to complete the treatment.
China has a large migrant worker population who leave the countryside to join the wage economy in China’s main towns and cities. Many of them practice unprotected sex and contract HIV/AIDS, which weakens their immune system and makes them more susceptible to tuberculosis. In addition, they live in circumstances that facilitate the transmission of the disease and impede their diagnosis and proper treatment.
Source: Ecns.cn
The China Red Ribbon Foundation has launched an annual program to advocate knowledge about HIV and AIDS prevention among migrant workers.
The program, which began on Wednesday and will be an annual event, recruits university students as volunteers to give "health bags" to migrant workers. Each bag includes such items as a pamphlet and a deck of cards printed with facts about HIV prevention, a cup, a mask, a nail cutter, a handkerchief and a pair of gloves.
The volunteers will also share knowledge about HIV prevention with the migrant workers through such means as lectures and games. More…
02/07/2014
HIV-Positive Students Sit Senior High School Entrance Exams
Source: Womenofchina.cn
Sixteen children affected by HIV in the Linfen Red Ribbon School in north China's Shanxi Province, sat their senior high school entrance exams on June 20, meaning that the school will have senior high school students in the new semester for the first time.
New teachers from a local leading senior high school will join the school and teach them in the next three years, despite the fact that the school's name won't appear on the children's graduation certificates.
Established in 2006 by President of the Linfen Hospital for Infectious Diseases Guo Xiaoping, the Linfen Red Ribbon School is China's first and only school for children affected by HIV/AIDS.
The school, which offers primary and junior middle school education, now has a total of 25 students, 16 of whom are in the third year of junior middle school.
During the first six years, the school ran without certification, so students could not register in the local education system, had no graduation certificate, and were not allowed to attend the high school entrance exam. In October 2011, the local government approved the school's certification and granted subsidies. More…
03/07/2014
Clinical, immunological, and virological outcomes of pediatric antiretroviral therapy in central China
Source: 7thspace.com/
Antiretroviral therapy (ART) reduces HIV-related mortality and morbidity substantially in children. The clinical characteristics, immunological and virological outcomes were evaluated in HIV-infected children receiving ART.
Methods: Twenty-six HIV-1-infected children receiving ART in Hubei province, China, were enrolled retrospectively in this study.
During the period of ART, plasma viral load, lymphocyte phenotype of CD4 and CD8 cells and clinical events were assessed.
Results: The median duration of ART was 41 months (18-72.3 months). In children showing clinical improvement, high viral suppression rate below log10 (2.7) copies/ml by the third months of ART was observed.
The median CD4 cell counts reached to 820.5/mul by 12 months and the median ratio of CD4/CD8 increased to 0.6 by 21 months. The counts of peripheral white blood cells and red blood cells decreased in the first 12 months, while Hb concentration, MCV and MCH increased (P <0.001).More…
06/07/2014
Should You Take a Chance With GlaxoSmithKline?
Source: wallstcheatsheet.com/
With shares of GlaxoSmithKline (NYSE:GSK) trading around $54, is GSK an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let’s analyze the stock with the relevant sections of our CHEAT SHEET investing framework:
T = Trends for a Stock’s Movement
GlaxoSmithKline is global healthcare group engaged in the discovery, development, manufacturing, and marketing of pharmaceutical products. These products are vaccines, over-the-counter medicines, and health-related consumer products. GlaxoSmithKline’s principal pharmaceutical products are medicines in these areas: respiratory, antivirals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV.
Peter Humphrey had not expected to be caught in the glare of a television camera from China Central Television, the state broadcaster, when he was escorted last August into a small room in a Shanghai detention centre. Humphrey, a British private investigator hired by GlaxoSmithKline to investigate whether a former Chinese employee was waging a smear campaign against the company, was asked to read a confession into what he was told would be a small police interrogation camera, according to people familiar with his case. Police informed him that it would help his situation. A month earlier Humphrey and Yu Yingzeng, his American wife and business partner, had been arrested on charges of illegally purchasing private information and operating an illegal business. Handcuffed and wearing an orange prison vest, Humphrey instead found himself recording a confession that would later be broadcast across the country. “He had no choice but to say what he had been told to say in front of a big camera instead of a small one,” said one person familiar with the trap. “He was extremely upset about it afterwards and the British government complained.” Shanghai police declined to comment. More…
08/07/2014
Research and Markets: Global Flow Cytometry Market Forecasts and Opportunities, 2018: Technology, Products & Services, Application & End User Analysis
Source:heraldonline.com
In this report, the global flow cytometry market has been segmented on the basis of products (instruments, reagents and consumables, software, services, and accessories) and applications (research, clinical, and industrial applications). The Research field commands a major chunk of the global flow cytometry market in 2013. This is attributed to the increasing applications of flow cytometry in drug discovery and development process, right from pre-clinical trials to target identification and throughput screening. However, the clinical applications segment is the fastest growing segment in this market, owing to the increasing prevalence coupled with intensifying adoption of flow cytometry techniques for the diagnosis and treatment of a number of diseases such as cancer, HIV/AIDS, and others.
The global flow cytometry market is dominated by North America, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). North America will continue to dominate the market in the forecast period (2013-2018). However, the Asia-Pacific region is expected to grow at the highest CAGR of 16% from 2013 to 2018.
Over the next five years, the growth of the market in the Asia-Pacific region is likely to be centered at Japan, China, and India. A number of factors such as various economic developments and growing prevalence to HIV/AIDS, growing number of research initiatives, increasing government support, growing awareness, and growing focus of both international and domestic players are driving the growth of the market in the Asia-Pacific region.
New product launches is the key strategy followed by the leading market players to ensure their growth in the market. Moreover, partnerships, agreements, collaborations and joint ventures, mergers and acquisitions, and expansions are some other growth strategies adopted by the industry players in the global market. More…
08/07/2014
The Dangerous Resurgence of Tuberculosis in China
Source: counterpunch.org
China now has the second largest tuberculosis epidemic -second only to India- with more than 1.3 million new cases of tuberculosis every year. What makes the situation particularly serious, however, is that, according to the Chinese Center for Disease Control, China has the largest number of patients with Multiple Drug Resistant Tuberculosis (MDR-TB), and that Extremely Resistant Drug Tuberculosis (XDR-TB) is also widespread. These facts show the need to step up efforts to combat the disease.
In 1993, the World Health Organization (WHO) instituted a cost-effective treatment of tuberculosis called DOTS (a directly observed treatment of a short course of drugs) that was very effective in combating TB in low-income countries. However, over time, patients began developing resistance to the drugs used for treatment, causing MDR-TB to spread.
Less than one-quarter of those believed to have MDR-TB have been diagnosed, according to the WHO, which facilitates the spreading of this serious form of the disease. “We have managed by a combination of complacency and incompetence to allow this bacillus to mutate to a virtually untreatable form,” wrote Dr. Zarir Udwadia, an Indian world expert on tuberculosis and author of the book Principles of Respiratory Medicine.
Tuberculosis becomes resistant to drugs in patients who don’t complete the treatment. The current treatment for non-resistant tuberculosis is relatively cheap and consists of drugs called first-line drugs for TB. In MDR-TB the patient is resistant to at least the two most powerful anti-TB drugs. This form of the disease is much more costly to treat, and it is also much more toxic (it has more serious side effects), which explains patients’ reluctance to complete the treatment.
China has a large migrant worker population who leave the countryside to join the wage economy in China’s main towns and cities. Many of them practice unprotected sex and contract HIV/AIDS, which weakens their immune system and makes them more susceptible to tuberculosis. In addition, they live in circumstances that facilitate the transmission of the disease and impede their diagnosis and proper treatment.
Address: 2-8-1, Tayuan Diplomatic Office Building
14, Liangmahe Nanlu, Dongwai Dajie
Beijing, 100600, P.R. China
Tel: (8610) 8532 2226
Fax: (8610) 8532 2228
email: china@unaids.org
Copyright © 2009-2011,All rights reserved